Takeda links with CellCentric on epigenetic target
This article was originally published in Scrip
Takedahas signed an agreement with CellCentric for the validation of a cancer-related protein identified by the UK firm as a possible therapeutic target. Takeda also has an option to acquire rights to the inhibitor development programme related to the target. CellCentric has a network of relationships with facilities conducting research into epigenetic disease mechanisms, through which it identifies targets for the generation of novel small-molecule drugs. Its investors include the Rainbow Seed Fund, which is funded by the UK Office of Science and Innovation to support the commercialisation of public research.
You may also be interested in...
US-based, China-focused CANbridge moves into cholestatic liver disease and enzyme replacement therapy via two deals. Plus deals involving LegoChem, TransThera, Morepen, Daiichi Sankyo, Geneseeq, Innocare, Biosplice, Sirnaomics and Walvax.
In this week's podcast version of Five Must-Know Things, hear about possible new life for Tecfidera, activist investors and GSK, a new mRNA vaccine in Europe, diversity in clinical trials, and a look at last year’s drug launches.
Argenx partners with Elektrofi and Iontas; China’s Qilu obtains global rights to Peptron’s antibody-drug conjugate and also ends co-development pact with Quantum Genomics.